ReviewBiomolecules2020
Extracellular Vesicles as Nanotherapeutics for Parkinson's Disease.
Review in Biomolecules, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Exosomes in depression: mechanistic insights, diagnostic potential, and therapeutic opportunities.Molecular psychiatry · 2026Review
- Colostrum Extracellular Vesicle Isolation, Characterization, and Function.Biomedicines · 2026Article
- SPROUTS_DB: An Implemented Database of Contaminants for Extracellular Vesicle Proteomics Studies.Proteomics · 2026Article
- Pathology-directed drug delivery strategies: How to overcome blood-brain barrier for the treatment of brain diseases.Acta pharmaceutica Sinica. B · 2026Review
- Plant-derived exosome-like nanovesicles: mechanisms and molecular understanding in neurological disorders with potential therapeutic applications.Drug delivery and translational research · 2025Review
- Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges.Molecular neurobiology · 2025Review
- Sperm epigenetics and sperm RNAs as drivers of male infertility: truth or myth?Molecular and cellular biochemistry · 2025Review
- Extracellular vesicle therapy in neurological disorders.Journal of biomedical science · 2024Review
- Extracellular Vesicles: The Next Generation of Biomarkers and Treatment for Central Nervous System Diseases.International journal of molecular sciences · 2024Review
- Platelet-derived microparticles and their cargos: The past, present and future.Asian journal of pharmaceutical sciences · 2024Review
- Label-free approaches for extracellular vesicle detection.iScience · 2023Review
- Thermostable Basic Fibroblast Growth Factor Enhances the Production and Activity of Human Wharton's Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles.International journal of molecular sciences · 2023Article
- Bio-Inspired Nanocarriers Derived from Stem Cells and Their Extracellular Vesicles for Targeted Drug Delivery.Pharmaceutics · 2023Review
- Review
- Alzheimer's and Parkinson's disease therapies in the clinic.Bioengineering & translational medicine · 2023Review
- Propagation of Parkinson's disease by extracellular vesicle production and secretion.Biochemical Society transactions · 2022Review
- Small Extracellular Vesicles Secreted by Nigrostriatal Astrocytes Rescue Cell Death and Preserve Mitochondrial Function in Parkinson's Disease.Advanced healthcare materials · 2022Article
- Sequestration of Inflammation in Parkinson's Disease via Stem Cell Therapy.International journal of molecular sciences · 2022Review
- Role of exosomes in the pathogenesis of inflammation in Parkinson's disease.Neural regeneration research · 2022Review
- Exosomes as Crucial Players in Pathogenesis of Systemic Lupus Erythematosus.Journal of immunology research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Extracellular vesicles (EVs) are naturally occurring membranous structures secreted by normal and diseased cells, and carrying a wide range of bioactive molecules. In the central nervous system (CNS), EVs are important in both homeostasis and pathology. Through receptor-ligand interactions, direct fusion, or endocytosis, EVs interact with their target cells. Accumulating evidence indicates that EVs play crucial roles in the pathogenesis of many neurodegenerative disorders (NDs), including Parkinson's disease (PD). PD is the second most common ND, characterized by the progressive loss of dopaminergic (DAergic) neurons within the Substantia Nigra pars compacta (SNpc). In PD, EVs are secreted by both neurons and glial cells, with either beneficial or detrimental effects, via a complex program of cell-to-cell communication. The functions of EVs in PD range from their etiopathogenetic relevance to their use as diagnostic tools and innovative carriers of therapeutics. Because they can cross the blood-brain barrier, EVs can be engineered to deliver bioactive molecules (e.g., small interfering RNAs, catalase) within the CNS. This review summarizes the latest findings regarding the role played by EVs in PD etiology, diagnosis, prognosis, and therapy, with a particular focus on their use as novel PD nanotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.